Advertisement

Characterization of Plasmalogen-Selective Phospholipase A2 from Bovine Brain

  • Hsiu-Chiung Yang
  • Akhlaq A. Farooqui
  • Lloyd A. Horrocks
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 416)

Abstract

Plasmalogens are hydrolyzed by a plasmalogen-selective phospholipase A2. This enzyme, purified from bovine brain, does not require Ca2+ and is localized in cytosol. It has a molecular mass of 39 kDa and is strongly inhibited by glycosaminoglycans, gangliosides, and sialoglycoproteins. These molecules may be involved in the regulation of its enzymic activity. Plasmalogen-selective phospholipase A2 plays an important role in the release of free fatty acids and platelet-activating factor during trauma.

Keywords

Bovine Brain Vasopressin Receptor Excitatory Amino Acid Receptor Smooth Muscle Cell Line Suicide Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Engelmann, B., Bräutigam, C., and Thiery, J. 1994, Plasmalogen phospholipids as potential protectors against lipid peroxidation of low density lipoproteins, Biochem. Biophys. Res. Commun. 204: 1235.PubMedCrossRefGoogle Scholar
  2. Farooqui, A.A., Yang, H.-C., and Horrocks, L.A. 1995, Plasmalogens, phospholipases A2, and signal transduction, Brain Res. Rev. (in press).Google Scholar
  3. Farooqui, A.A. and Horrocks, L.A. 1991, Excitatory amino acid receptors, neural membrane phospholipid metabolism and neurological disorders, Brain Res. Rev. 16: 171.PubMedCrossRefGoogle Scholar
  4. Felde, R. and Spiteller, G. 1995, Plasmalogen oxidation in human serum lipoproteins, Chem. Phys. Lipids 76: 259.PubMedCrossRefGoogle Scholar
  5. Hazen, S.L. and Gross, R.W. 1992, Identification and characterization of human myocardial phospholipase A2 from transplant recipients suffering from end-stage ischemic heart disease, Circ. Res. 70: 486.PubMedCrossRefGoogle Scholar
  6. Horrocks, L.A. and Sharma, M. 1982, Plasmalogens and 0-alkyl glycerophospholipids, in: “Phospholipids, New Comprehensive Biochemistry, Vol. 4,” 51–93Google Scholar
  7. J.N. Hawthorne, G.B. Ansell, eds., Elsevier Biomedical Press, Amsterdam.Google Scholar
  8. Jurkowitz-Alexander, M., Ebata, H., Mills, J.S., Murphy, E.J., and Horrocks, L.A. 1989, Solubilization, purification, and characterization of lysoplasmalogen alkenylhydrolase (lysoplasmalogenase) from rat liver microsomes, Biochim. Biophys. Acta 1002: 203.PubMedCrossRefGoogle Scholar
  9. Kramer, R.M., Jakubowski, J.A., and Deykin, D. 1988, Hydrolysis of 1-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine, a common precursor of platelet-activating factor and eicosanoids, by human platelet phospholipase A2, Biochim. Biophys. Acta 959: 269.PubMedCrossRefGoogle Scholar
  10. Nieto, M.L., Velasco, S., and Crespo, M.S. 1988, Biosynthesis of platelet-activating factor in human polymorphonuclear leukocytes, J. Biol. Chem. 263: 2217.PubMedGoogle Scholar
  11. Paltauf, F. 1994, Ether lipids in biomembranes, Chem. Phys. Lipids 74: 101.PubMedCrossRefGoogle Scholar
  12. Uemura, Y., Lee, T., and Snyder, F. 1991, A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway, J. Biol. Chem. 266: 8268.PubMedGoogle Scholar
  13. Yang, H.-C., Farooqui, A.A., and Horrocks, L.A. 1994, Effects of glycosaminoglycans and glycosphingolipids on cytosolic phospholipases A2 from bovine brain, Biochem. J. 299: 91.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Hsiu-Chiung Yang
    • 1
  • Akhlaq A. Farooqui
    • 1
  • Lloyd A. Horrocks
    • 1
    • 2
  1. 1.Ohio State UniversityDepartment of Medical BiochemistryColumbusUSA
  2. 2.Neurovation Inc.ColumbusUSA

Personalised recommendations